The preparation, handling and use of intravesical bacillus Calmette-Guerin for the management of stage Ta, T1, carcinoma in situ and transitional cell cancer.
The increasing use of bacillus Calmette-Guerin in the treatment of patients with low stage bladder cancer will inevitably bring attention to problems of proper use and toxicity. There is a need to identify patients who are most likely to benefit from this therapy and those who may be at risk for serious complications.
Brosman
S A
SA
Department of Surgery/Urology, UCLA Medical Center.
Lamm
D L
DL
D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000628:therapy*; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D006801:Humans; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D001500:BCG Vaccine